Hemispherx (HEB) Submits Reports of New Preclinical Data on Ampligen; Sees No Boost in Undesirable Cytokines
Tweet Send to a Friend
Hemispherx Biopharma, Inc. (Amex: HEB) stated that on January 14, 2010, the Company submitted reports of new preclinical data regarding ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
